Sebastian Bauer, MD (he/him/his)

Director Sarcoma Center
Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany, Germany

Dr. Bauer graduated from Medical School in Würzburg, Germany and received is training in Internal Medicine and Medical Oncology at the University Hospital in Essen, Germany. He currently directs the Sarcoma Center at the West German Cancer Center in Essen and a translational sarcoma research group. He is consultant oncologist at the Dept. of Medical Oncology and co-leads the Adolescent and Young Adults (AYA) program at the University in Essen.

Poster(s):

• (P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY

• (P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY

• (P 121) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES IN PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR

• (P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA

• (P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1

• (P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS